Whole-brain radiotherapy versus stereotactic radiosurgery for patients in recursive partitioning analysis classes 1 and 2 with 1 to 3 brain metastases-Reference-Cited by-同舟云学术

Whole-brain radiotherapy versus stereotactic radiosurgery for patients in recursive partitioning analysis classes 1 and 2 with 1 to 3 brain metastases

Published:2007 Issue:10 Volume:110 Page:2285-2292
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Rades Dirk,Pluemer Andre,Veninga Theo,Hanssens Patrick,Dunst Juergen,Schild Steven E.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference19 articles.

1. Intracerebral metastases in solid-tumor patients: Natural history and results of treatment

2. Prognosis of patients treated for intracranial metastases with whole-brain irradiation

3. Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes?

4. Radiosurgery for brain metastases: a score index for predicting prognosis

5. A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognosis versus Actual Outcomes in Stereotactic Radiosurgery of Brain Metastases: Reliability of Common Prognostic Parameters and Indices;Current Oncology;2024-03-26

2. Efficacy of stereotactic radiosurgery as single or combined therapy for brain metastasis: A systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2023-06

3. Stereotactic Radiotherapy or Whole-Brain Irradiation Plus Simultaneous Integrated Boost After Resection of Brain Metastases;Anticancer Research;2023-05-29

4. The First Survival Score for Patients Treated with Whole-Brain Radiotherapy Plus Simultaneous Integrated Boost for Brain Metastases;Biology;2023-04-12

5. Whole-Brain Radiotherapy Combined With Anlotinib for Multiple Brain Metastases From Non-small Cell Lung Cancer Without Targetable Driver Mutation: A Single-Arm, Phase II Study;Clinical Medicine Insights: Oncology;2022-01